Battered King picks new CFO after months of questions

King Pharmaceuticals appointed Joseph Squicciarino chief financial officer.
News of the former Revlon CFO's appointment buoyed the troubled company's stocks, battered in recent months by a botched merger and questions over past earnings statements. A bid by Mylan Laboratories to acquire King was scuttled in February after the Bristol, Tenn.-based company said it would have to restate earnings results from 2002 through the first half of 2004. Squicciarino, who worked for
Johnson & Johnson and Bristol- Myers Squibb before joining Revlon, succeeds James Lattanzi, whose retirement was announced in April.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.